Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2014', provides an overview of the Fibrinogen Deficiency (Factor I Deficiency)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fibrinogen Deficiency (Factor I Deficiency) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibrinogen Deficiency (Factor I Deficiency) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Fibrinogen Deficiency (Factor I Deficiency) Overview 6 Therapeutics Development 7 Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview 7 Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis 8 Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies 9 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies 12 Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development 13 Biotest AG 13 China Biologic Products, Inc. 14 LFB S.A. 15 Octapharma AG 16 Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 23 fibrinogen concentrate (human) - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 fibrinogen concentrate (human) - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 fibrinogen concentrate (human) - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 fibrinogen concentrate (human) - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Fibrinogen Deficiency (Factor I Deficiency) - Recent Pipeline Updates 28 Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products 29 Fibrinogen Deficiency (Factor I Deficiency) - Product Development Milestones 30 Featured News & Press Releases 30 Dec 06, 2012: Biotest Initiates Phase I/II Clinical Study Of Human Fibrinogen Concentrate To Treat Bleeding Disorders 30 Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency), H2 2014 7 Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Biotest AG, H2 2014 13 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by China Biologic Products, Inc., H2 2014 14 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by LFB S.A., H2 2014 15 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Octapharma AG, H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 18 Number of Products by Stage and Mechanism of Action, H2 2014 19 Number of Products by Stage and Route of Administration, H2 2014 21 Number of Products by Stage and Molecule Type, H2 2014 22 Fibrinogen Deficiency (Factor I Deficiency) Therapeutics - Recent Pipeline Updates, H2 2014 28 Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products, H2 2014 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.